Imclone systems (IMCL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL)

IMCL 0.159

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (2016)	2/13/2002 11:24:50 PM
From: Cacaito	Read Replies (1) of 2515

" The contract allows Bristol-Myers to withdraw if there is a "significant concern regarding a regulatory or patient safety issue that would seriously impact the long-term viability of the product." Above from today New York Times. There are very serious "concerning" issues about the the regulatory process that could impact the long term viability of the product. At the least, Bmy could step out and save $800M, they would still own the 20% of Imcl. But, Bmy wants more, Bmy wants the most they can get. In my view BMY will prevail on their terms.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next